320 related articles for article (PubMed ID: 21381287)
1. [Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].
Mingot Castellano ME
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():39-43. PubMed ID: 21381287
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
3. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
[TBL] [Abstract][Full Text] [Related]
4. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Nurden AT; Viallard JF; Nurden P
Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
6. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
7. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
[TBL] [Abstract][Full Text] [Related]
8. Platelet production bolstered with romiplostim approval.
Morrow T
Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
[No Abstract] [Full Text] [Related]
9. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
Yang BB; Doshi S; Arkam K; Franklin J; Chow AT
Clin Pharmacokinet; 2016 Sep; 55(9):1045-58. PubMed ID: 27056734
[TBL] [Abstract][Full Text] [Related]
10. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
Raval JS; Redner RL; Kiss JE
J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
[TBL] [Abstract][Full Text] [Related]
13. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
Meletis J; Katsandris A; Raptis SD; Mantzourani M
Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
[TBL] [Abstract][Full Text] [Related]
15. Emperipolesis in a patient receiving romiplostim.
Cooper N; Bain BJ
Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
[No Abstract] [Full Text] [Related]
16. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
18. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
19. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
20. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
